DOCSLIB.ORG

Drug Repurposing Compound Library (96-Well)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Repurposing Compound Library (96-Well) • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Drug Repurposing Compound Library (96-well) Product Details: Catalog Number: CS-L035 Formulation: A collection of 3588 bioactive compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L035-1 1 2 3 4 5 6 7 8 9 10 11 12 Flavopiridol a Empty Vonoprazan Peretinoin Tomivosertib Faropenem Flavopiridol (Hydrochlorid Semagacesta Mitoquinone Taranabant Delpazolid Empty daloxate e) t (mesylate) Varenicline AQ-13 b Empty DSM265 GSK- Varenicline (Hydrochlorid Varenicline Trifarotene 9-amino-CPT dihydrochlorid Remetinostat Isavuconazon Empty 2881078 e) (Tartrate) e ium (sulfate) K-604 c Empty Diroximel Nevanimibe dihydrochlorid Pactimibe Pactimibe Linaprazan BFH772 Odanacatib Cadazolid Treprostinil Empty fumarate hydrochloride e (sulfate) Rilmenidine d Empty Paquinimod AEE788 Plerixafor Esaxerenone Visomitin (hemifumarat Rilmenidine Fisogatinib FT011 GSK2256098 Empty e) (phosphate) e Empty Avadomide Aprepitant (S)-Crizotinib MSDC 0160 Abscisic acid Tempol Flopropione Acriflavine Davercin Spiramycin Empty Sodium Landiolol AZD5153 (6- f Empty stibogluconat Saponins (hydrochlorid BMS-986020 BMS-986020 Ticagrelor Axitinib Hydroxy-2- Fosfluconazol Pipamperone Empty e e) (sodium) naphthoic e Pirmenol g Empty Eganelisib HT-2157 Lanabecestat CXD101 Ritlecitinib Setogepram Rimacalib (hydrochlorid D-Serine Futibatinib Empty (sodium salt) e) TAK-659 h Empty 3-AP BGP-15 (hydrochlorid Navitoclax ABX464 Bisantrene Zibotentan Acelarin Simurosertib Olcegepant Empty e) Plate layout: CS-L035-2 1 2 3 4 5 6 7 8 9 10 11 12 (2- Empty Choline Sarcosine Q203 Brensocatib Acetylcholine MK-8998 Hydroxypropy TG100-115 Tesmilifene Filibuvir Empty a (bitartrate) (iodide) l)-β- (fumarate) Milademetan b Empty T807 JNJ- Vorapaxar Asenapine Silodosin Barasertib- (tosylate Barasertib Vadadustat Veliparib Empty 39758979 HQPA hydrate) Veliparib Trilaciclib c Empty Iberdomide FK614 (dihydrochlori Allopurinol Gestrinone Ralfinamide (hydrochlorid Zanubrutinib Ibuprofen LY3214996 Empty de) riboside e) piconol d Empty AZD-5991 Linrodostat Avapritinib GDC-0077 GSK3326595 BMS-986158 Roblitinib Bosutinib Gefapixant Nilotinib Empty Nilotinib Tedatioxetine e Empty (monohydroc Tozasertib Olaparib Ilaprazole Aticaprant (hydrobromid GSK2982772 Ziritaxestat EDO-S101 Danusertib Empty hloride e) Dasatinib Blarcamesine f Empty Dasatinib (hydrochlorid BMS-986142 TG 100801 Miridesap (hydrochlorid Linsitinib TNP-470 Sepantronium CM-4620 Empty e) e) (bromide) Ruboxistaurin g Empty Prostaglandin (hydrochlorid Selitrectinib CPI-444 Navarixin AZD4635 BMS-754807 Rucaparib Rilapladib Sorafenib Empty E2 e) (Camsylate) Tandutinib h Empty Sorafenib Tandutinib (hydrochlorid Linperlisib Cediranib Apimostinel Amuvatinib Dovitinib Pazopanib Masitinib Empty (Tosylate) e) (lactate) Plate layout: CS-L035-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Retaspimycin a Empty Masitinib (Hydrochlorid Tanespimycin BIIB021 Luminespib Everolimus Rapamycin Vorinostat Ixabepilone Panobinostat Empty (mesylate) e) Gaboxadol b Empty Belinostat Bortezomib Motesanib Motesanib Midostaurin THIP (hydrochlorid Saracatinib Telaprevir Boceprevir Empty (Diphosphate) e) Afatinib c Empty Danoprevir Mericitabine Simeprevir RAF265 PD0325901 Sunitinib Vandetanib Afatinib (dimaleate) Edoxaban Empty Edoxaban Dabigatran d Empty Edoxaban (tosylate Betrixaban Dabigatran etexilate Linagliptin Saxagliptin Tarenflurbil Narlaprevir Gusacitinib Empty (tosylate) monohydrate) etexilate (mesylate) BET e Empty LY3200882 Repotrectinib bromodomain Zuranolone AAI101 Proxalutamid Doramapimod Amibegron Desidustat Neflamapimo Empty inhibitor e hydrochloride d Regorafenib f Empty Toceranib Toceranib Regorafenib Bepridil (monohydrate BMS-690514 Proglumide Brivanib Brivanib Talniflumate Empty (phosphate) hydrochloride ) (sodium) (alaninate) Tirbanibulin Fasudil Raltegravir g Empty Foretinib Stiripentol Tirbanibulin (dihydrochlori Tirbanibulin (Hydrochlorid Enzastaurin Sotrastaurin Raltegravir (potassium Empty de) (Mesylate) e) salt) MK-2206 Canertinib Samuraciclib h Empty (dihydrochlori GW-870086 MAK683 Canertinib AZD7624 (dihydrochlori (hydrochlorid Seclidemstat Ensartinib Trimetrexate Empty de) de) e) hydrochloride Plate layout: CS-L035-4 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Semaxinib Sutezolid Linezolid Emricasan CTS-1027 VX-702 Asciminib Islatravir Losmapimod PH-797804 Empty Fedratinib b Empty IDH-305 Cintirorgon Vorasidenib Pamiparib Lanifibranor Talmapimod Fedratinib (hydrochlorid Milciclib Vismodegib Empty e hydrate) Dapagliflozin Empty Balapiravir Pralatrexate Capsaicin Dapagliflozin ((2S)-1,2- Canagliflozin Ixazomib Ixazomib Delanzomib TAK-715 Empty c propanediol, citrate Daclatasvir Melflufen d Empty (dihydrochlori Daclatasvir Eprotirome Fasiglifam Pevonedistat Dinaciclib Cobicistat Lexibulin (hydrochlorid Tipifarnib Empty de) hydrochloride e) Pomaglumeta Pimonidazole e Empty d methionil Orteronel Rifalazil (hydrochlorid Orantinib Fidarestat Meclinertant Darapladib Telatinib Tasquinimod Empty (hydrochlorid e) Tariquidar Empty PF 04531083 Sulopenem Piromelatine Betulinic acid Varlitinib Eniluracil Evofosfamide Tegobuvir Tariquidar (methanesulf Empty f onate, Sarpogrelate g Empty Nelotanserin Temanogrel Ketanserin Ketanserin Nomegestrol (hydrochlorid SRX246 Ponesimod Nevirapine Delavirdine Empty (tartrate) acetate e) (mesylate) Gatifloxacin h Empty Efavirenz Rilpivirine GSK 3 Gatifloxacin (hydrochlorid Flurbiprofen Valproic acid BNC210 Valproic acid 5-Azacytidine Empty Inhibitor IX e) (sodium salt) Plate layout: CS-L035-5 1 2 3 4 5 6 7 8 9 10 11 12 Trabodenoso Alagebrium Rucaparib a Empty Lobaplatin Zamicastat MMV390048 n Liarozole chloride Bimosiamose (phosphate) Rucaparib Niraparib Empty Niraparib b Empty Lidorestat (hydrochlorid Niraparib PF-00446687 Vapendavir Larazotide SB-705498 Carcainium BIO-11006 Salfaprodil Empty e) (tosylate) (diphosphate) (acetate) (chloride) (acetate) (free base) Chloroquinox c Empty Salfaprodil Tefinostat Arimoclomol Neticonazole Tiaprofenic Mitoguazone Voclosporin aline Hydrocortison Centhaquin Empty (maleate) acid sulfonamide e buteprate Nebentan Ningetinib d Empty Pridopidine Saredutant S 3304 Nebentan (potassium) MAP4343 Tosylate Ningetinib PZ-128 PF-03463275 Empty Delapril Asimadoline e Empty Bacitracin Selamectin Almitrine Azosemide β-Elemene (hydrochlorid Deserpidine AZD4205 Tetrahydrobio (hydrochlorid Empty mesylate e) pterin e) Clodronate f Empty Epristeride Tropifexor PAT-1251 Abrocitinib AZD-8529 AZD-8529 Arundic Acid Ectoine (disodium Benorilate Empty (mesylate) tetrahydrate) Potassium 5- Desoxycortico g Empty guaiacolsulfo Inosine Acetylsalicylic A40926 Cilomilast Ritanserin Hyaluronidas sterone Isosulfan blue Rezafungin Empty nate pranobex acid e pivalate (acetate) Ganaplacide Almorexant h Empty Armillarisin A Ferric maltol MSDC-0602 (hydrochlorid GET73 Almorexant (hydrochlorid Bitopertin Pemetrexed Pemetrexed Empty e) e) (disodium) Plate layout: CS-L035-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com 1 2 3 4 5 6 7 8 9 10 11 12 Inosine 5'- Lanicemine Melitracen a Empty Raltitrexed monophosph (dihydrochlori AZD5423 (hydrochlorid Promestriene Sultiame (Z)- Brequinar PF-04937319 Empty ate (disodium de) e) Thiothixene Nolatrexed b Empty Gamithromyci GW 501516 Cefodizime Cefodizime Emedastine Talazoparib Pretomanid Delamanid dihydrochlorid Arterolane Empty n (sodium) tosylate e Foliglurax c Empty Vipadenant (monohydroc Aripiprazole Clotrimazole Istradefylline Preladenant Icatibant Apararenone Padsevonil Poseltinib Empty hloride) Lauroxil (acetate) Seltorexant d Empty Rosiptor Seltorexant (hydrochlorid Sofpironium Tucidinostat Vamorolone Vorolanib Acrizanib Balovaptan Baloxavir Empty e) (bromide) marboxil Inarigivir e Empty Baloxavir Dorzagliatin soproxil Mavacamten Praliciguat Razuprotafib Tapinarof Adavivint Alobresib Elenbecestat Empty Parsaclisib f Empty Enarodustat Firibastat Fulacimstat Lazertinib Olinciguat (hydrochlorid Vecabrutinib Belvarafenib Cilofexor Difamilast Empty e) Lanraplenib Tepilamide Valemetostat g Empty Edicotinib Lanraplenib (succinate) Licogliflozin Nemorexant Nidufexor Pemigatinib Tegatrabetan fumarate (tosylate) Empty Acoramidis h Empty Odevixibat Reldesemtiv Soticlestat Danicamtiv Selgantolimo Danegaptide Ziresovir (hydrochlorid Giredestrant Posenacaftor Empty d Hydrochloride e) (sodium) Plate layout: CS-L035-7 1 2 3 4 5 6 7 8 9 10 11 12 Cerivastatin a Empty Rezivertinib Tolebrutinib Zandelisib Camicinal Aniracetam CX516 Mibampator S 18986 Farampator (sodium) Empty Gemcabene Arachidonic Momelotinib b Empty ASTX660 Gemcabene (calcium) IRAK4-IN-7 acid BMS-813160 Momelotinib sulfate Vadimezan Ensulizole Empty Obatoclax Lenvatinib Pomalidomid c Empty (Mesylate) Alisertib MK-0752 Tivozanib Crisaborole Tavaborole Lenvatinib (mesylate) Amonafide e Empty Trametinib d Empty ENMD-2076 ENMD-2076 Adavosertib Tozadenant Ibrutinib Ibrutinib Trametinib (DMSO ZSET1446 Rivastigmine Empty (Tartrate) (Racemate) solvate) (tartrate) Alendronate e Empty Risperidone Elinogrel MK-0773 Fingolimod
Load more

Recommended publications
  • Domains: 1. Optimizing Medication Use, Using Front- and Back Office Strategies 2
    A SUPPLEMENTARY TABLES Table S1: Domains and themes in the action plan of the Belgian Government (2015-2020) Domains: 1. Optimizing medication use, using front- and back office strategies 2. Continuity of pharmacotherapy in light of transmural care 3. Scientific skills of the hospital pharmacist 4. Transfer of information to and communication with the patient Themes: 2015: anchoring the minimal conditions for the application of clinical pharmacy 2016: development of a structured method for the anamnesis, registration and communication of the medication on admission and discharge 2017: application of clinical pharmacy for specific therapies 2018: application of risk screening for patient groups 2019: application of risk screening for medication groups or pathologies 2020: evaluation of the development of clinical pharmacy in the Belgian hospitals and evaluation of the action plan 2015-2020 Table S2: Anatomical and therapeutic classes of the drugs involved in the discrepancies detected after medication reconciliation n (%) Example(s) of discrepancy Gastro-intestinal system 43 (35.2%) antacids 6 O: antacid PRN antihistaminics 1 O: ranitidine 150 mg 1 pd proton pump inhibitors 5 O: pantoprazole 20 mg 1 pd propulsives 3 O: domperidone PRN; N: alizapride laxatives 9 O: macrogol PRN or 1 pd, bisacodyl PRN or 1 pd antipropulsives 2 O: loperamide 1 pd probiotics 1 O: frequent need for probiotics antidiabetics 1 D: dose repaglinide unknown multivitamins 5 O: multivitamins 1 pd vitamin D 5 O: vitamin D 1 per week vitamin B 2 N: vitamin B complex
    [Show full text]
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • Beyond Monoamines Towards the Development of Novel Antidepressants Oltre Le Monoamine Al Fine Di Sviluppare Nuovi Farmaci Antidepressivi
    Original article • Articolo originale Beyond monoamines towards the development of novel antidepressants Oltre le monoamine al fine di sviluppare nuovi farmaci antidepressivi M. Fornaro1,2 1 Department of “Scienze della Formazione”, University of Catania, Italy; 2 Department of Psychiatry, Veteran Affairs (VA) Hospital, University of California (UCSD), La Hoya, San Diego, CA, USA Summary ated giving priority to RCTs and meta-analyses. At present, the pharmacological management of depression appears is Objective characterized by a wide variety of different augmentation or Herein, a concise review is presented on the current and most switching approaches (Fig. 1). Nonetheless, response rates promising antidepressant pharmacological agents for manage- remain substantially unsatisfactory, thus prompting for the ment of depression. development of novel agents with different mechanisms of action. Materials and methods A PubMed search (1966 - February 2012) was performed using Conclusions the following keywords or their combination: “depression”; Shifting the interest for novel antidepressant drugs beyond the “major depressive disorder”: “antidepressants”; “novel antide- monoaminergic modulation represents (Tables I-III) an intriguing pressant targets”; “monoamine”; “novel antidepressants”. Ad- opportunity to enhance response rates of depression, although ditional literature sources, including most authoritative and up- other issues, including revision of current nosological bounda- dated edited books or pamphlets were examined accordingly.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Analysis of Metals in Surface Water Samples
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ
    [Show full text]
  • Spectrofluorometric Determination of Some Β-Blockers in Tablets And
    ORIGINAL ARTICLES Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia Spectrofluorometric determination of some b-blockers in tablets and human plasma using 9,10-dimethoxyanthracene-2-sodium sulfonate H. Abdine, M. A. Sultan, M. M. Hefnawy, F. Belal Received April 16, 2004, accepted June 2, 2004 Prof. Dr. F. Belal, Department of Pharmaceutical Chemistry, College of Pharmacy, P.O.Box 2457, King Saud University, Riyadh 11451, Saudi Arabia [email protected] Pharmazie 60: 265–268 (2005) A simple and sensitive spectrofluorometric method was developed for the quantitative determination of some b-blockers, namely arotinolol, atenolol and labetalol as hydrochloride salts. The method is based on the reaction of these drugs as n-electron donors with the fluorogenic reagent 9,10-dimethoxy-2- anthracene sulfonate (DMAS) as p-acceptor in acidic medium. The obtained ion-pairs were extracted into chloroform and measured spectrofluorometrically at 452 nm after excitation at 385 nm. The fluor- escence intensity-concentration plots are rectilinear over the ranges of 0.5–5 mg Á ml1, 1.0–11.0 mg Á ml1 and 0.6–6.4 mg Á ml1 for labetalol, atenolol and arotinolol, respectively. The different parameters affect- ing the reaction pathway were thoroughly studied and optimized. No interference was observed from the common pharmaceutical excipients. The proposed method was successfully applied to the analy- sis of tablets and the results were statistically compared with those obtained by reference methods. The method was further extended to the in vitro determination of the drugs in spiked human plasma, the% recoveries (n ¼ 3) ranged from 96.98 Æ 1.55 to 98.28 Æ 2.19.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Research in Your Backyard Developing Cures, Creating Jobs
    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
    [Show full text]
  • <I>Iguana Iguana</I>
    Journal of the American Association for Laboratory Animal Science Vol 58, No 6 Copyright 2019 November 2019 by the American Association for Laboratory Animal Science Pages 810–816 Use of Rodent Sedation Tests to Evaluate Midazolam and Flumazenil in Green Iguanas (Iguana iguana) Thais F Bressan, Thayanee Sobreira, and Adriano B Carregaro* This study aimed to evaluate the applicability of rodent behavioral tests to assess the effects of midazolam and flumazenil in green iguanas. Four tests commonly used to assess sedation in rodents—the open field test, forced swim test, behavioral scale, and traction test—were conducted in 10 juveniles iguanas. The animals received midazolam (2 mg/kg IM) or 0.9% NaCl (0.4 mL/kg IM), and the tests were conducted between 0 and 300 min thereafter. To verify the effects of midazolam and flumazenil, the most informative tests from the evaluation stage and the limb withdrawal latency time (LWLT) were used. All 10 iguanas were tested under 4 conditions, as follows: MS, midazolam (2 mg/kg IM), followed 30 min later by 0.9% NaCl (0.4 mL/kg IM); FS, flumazenil (0.05 mg/kg IM), followed by 0.9% NaCl (0.4 mL/kg IM) 30 min later; MF, midazolam (2 mg/ kg IM), followed by flumazenil (0.05 mg/kg IM) 30 min later; and CON, 0.9% NaCl (0.4 mL/kg IM). The behavioral scale and the forced swim test showed the best detection of the onset, peak effect, and the differences between the sedated and con- trol iguanas, with testing done between 15 and 240 min after drug administration.
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]